Sensibilidad a fluconazol y voriconazol de aislamientos de Candida spp., obtenidos de mucosa oral de pacientes con sida Sensitivity to Fluconazol and Voriconazol in Candida spp. isolates from the oral mucosa of HIV positive patients

Article English OPEN
Carolina Gutiérrez; Catalina de Bedout; Angela María Tobón; Luz Elena Cano; Myrtha Arango; Angela María Tabares; Angela Restrepo;
(2007)
  • Publisher: Asociación Colombiana de Infectología
  • Journal: Infectio (issn: 0123-9392)
  • Subject: voriconazole | susceptibility | antimicóticos | resistencia | sida | ntifungal | fluconazol, | resistance | fluconazole | sensibilidad | RM1-950 | RC109-216 | Therapeutics. Pharmacology | Infectious and parasitic diseases | voriconazol, | AIDS | Candida

Se determinó la sensibilidad al fluconazol y al voriconazol de aislamientos de Candida spp. obtenidos de la mucosa oral de 54 pacientes con sida hospitalizados en la ESE Hospital La María (Medellín, Colombia). Además, se comprobó la especie de tales aislamientos. Los pa... View more
  • References (23)
    23 references, page 1 of 3

    1. MARTÍNEZ M, LÓPEZ-RIBOT JL, KIRKPATRICK WR, BACHMANN SP, PEREA S, RUESGA MT, PATTERSON TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002;2:515- 24.

    2. SANT'ANA P, MILAN EP, MARTINEZ R, QUEIROZ-TELLES F, FERREIRA MS, ALCANTARA AP, CARVALHO MT, COLOMBO AL. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz. 2002;97:253-7.

    3. FIDEL JRPL, VÁZQUEZ JA, SOBEL JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;12:80-96.

    4. REDDING SW, KIRKPATRICK WR, DIB O, FOTHERGILL AW, RINALDI MG, PATTERSON TF. The epidemiology of non albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist. 2000;20:78-81.

    5. COWEN LE, SANGLARD D, CALABRESE D, SIRJUSINGH C, ANDERSON JB, KOHN LM. Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol. 2000;182:1515- 22.

    6. STRINGARO A, MOLINARI A, CALCABRINI A, ARANCIA G, CEDDIA PG, CIANFRIGLIA M, POLONI F, MONDELLO F, ANGIOLELLA L, DE BERNARDIS F, CASSONE A. Detection of human P-glycoproteinlike molecule in azole-resistant Candida albicans from HIV+ patients. Microb Drug Resist. 2002;8:235-44.

    7 . LARISSA M, PODUST T, POULOS L, WATERMAN MR. Crystal structure of cytochrome P450 14a-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. PNAS. 2001;98:3068-73.

    8. PFALLER MA, DIEKEMA DJ, SHEEHAN DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19:435- 47.

    9. PFALLER MA, DIEKEMA DJ, REX JH, ESPINEL-INGROFF A, JOHNSON EM, ANDES D, CHATURVERDI V, GHANNOUM MA, ODDS FC, RINALDI MG, SHEEHAN DJ, TROKE P, WALSH TJ, WARNOCK DW. Correlation of MIC with outcome for Candida species tested against voriconazol: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819-26.

    10. PFALLER MA, DIEKEMA DJ, RINALDI MG, BARNES R, HU B, VESELOV AV, TIRABOSCHI N, NAGY E, GIBBS DL. Results from the Artemis Disk global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005;43:5848-59.

  • Metrics
    No metrics available
Share - Bookmark